Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Exclusion Criteria

• •1. Endometrioid, clear cell, mucinous, or sarconmatous histology; mixed tumors containing any of the above or low grade/borderline ovarian tumor
• •2. More than one line of prior chemotherapy before current/planned triplet therapy
• •3. PD (progressive disease) while on or following platinum-based therapy
• •4. Prior or whole-pelvis or wide-field radiotherapy
• •5. \> Grade 1 peripheral neuropathy
• •6. History of or concurrent ocular disorders
• •7. Grade 4 thromboembolic events
• •8. Not appropriate for bevacizumab treatment
• •9. Requiring use of folate-containing supplements
• •10. Prior hypersensitivity to monoclonal antibodies
• •11. Pregnant or breatfeeding women
• •12. Received prior MIRV or other FRα-targeting agents
• •13. Untreated or symptomatic central nervous system metastases
• •14. History of other malignancy within 3 years prior to signing study consent